RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹3,003.80up ₹159.80 (5.62%)BSE ₹2,995.65
Share price at the NSE close on 29 Oct 2026. Previous close ₹2,844.00.
29 Oct: open ₹2,780.00, high ₹3,050.00, low ₹2,779.90
52-week range of traded prices to 29 Oct 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,968 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 7.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.80%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 17.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,36,34643.2% delivered
RPG Life Sciences board meetings
120 filed, newest first. Page 2 of 3.
Jun 2020
5 Jun · Board meeting
May 2020
29 May · Board meeting
Mar 2020
11 Mar · Board meeting
Jan 2020
31 Jan · Board meeting
Dec 2019
31 Dec · Board meeting
Oct 2019
30 Oct · Board meeting
23 Oct · Board meeting
Jul 2019
30 Jul · Board meeting
23 Jul · Board meeting
Apr 2019
29 Apr · Board meeting
22 Apr · Board meeting
Feb 2019
5 Feb · Board meeting
Jan 2019
29 Jan · Board meeting
Nov 2018
5 Nov · Board meeting
Oct 2018
29 Oct · Board meeting
Sep 2018
27 Sep · Board meeting
Jul 2018
27 Jul · Board meeting
May 2018
2 May · Board meeting
Apr 2018
Feb 2018
3 Feb · Board meeting
Jan 2018
Nov 2017
10 Nov · Board meeting
Aug 2017
4 Aug · Board meeting
Jul 2017
Apr 2017
Jan 2017
Oct 2016
Jul 2016
May 2016
Apr 2016
Mar 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
Jan 2015
13 Jan · Board meeting
Inter-alia, to consider and approve the unaudited financial results for the quarter ended December 31, 2014.
Oct 2014
9 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2014.Further, as per SEBI(Prohibition of Insider Trading Regulation), 1992 and the Code of Conduct adopted by the Company, the 'Trading Window' for trading in the Company's securities shall remain closed for the promoters, Directors and Designated Employees of the Company from October 10, 2014 to October 21, 2014(both days inclusive) for the purpose of declaration of quarterly financial results.
Jul 2014
14 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2014.
Apr 2014
Jan 2014
28 Jan · Board meeting
Inter-alia, to consider and approve the unaudited financial results for the quarter ended December 31, 2013. Further, as per SEBI (Prohibition of Insider Trading Regulation), 1992 and the Code of Conduct adopted by the Company, the 'Trading Window' for trading in the Company's securities shall remain closed for the promoters, Directors and Designated Employees of the Company from January 29, 2014 till February 10, 2014 (both days inclusive) for the purpose of declaration of quarterly financial results.
Oct 2013
7 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2013.
Jul 2013
16 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2013.
May 2013
8 May · Board meeting
Board of Directors of the Company at its meeting held on May 07, 2013 has re-appointed Mr. Ajit Singh Chouhan as Managing Director of the Company for a further period of 3 years w.e.f. April 09, 2013, subject to the approval of the members at the ensuing Annual General Meeting.
Apr 2013
25 Apr · Board meeting
Inter alia, to consider and approve the following: (1) Audited financial results for the year ended on March 31, 2013; and (2) Recommendation of dividend for the year 2012-13, if any.
Jan 2013
28 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended December 31, 2012.